Evogene Ltd.
Evogene Ltd. (EVGN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EVGN · as of Jun 8, 2026
Key Statistics
Explore Evogene Ltd. Data
evgn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 100.0%
The EVGN analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $2.15, representing +251.59% upside from the current price of $0.61.
Competitors & Peers
evgn competitorsEVGN
AEON
BOLT
CING
CLRB
COCPStock Performance
Full HistoryAbout Evogene Ltd.
Evogene Ltd. along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as h…
what is evogene ltd. · evgn stock overview · evogene ltd. company profile · who is evogene ltd. ceo · evgn NASDAQ · evogene ltd. headquarters · evogene ltd. business segments
About Stock Overview & Key Data
Evogene Ltd. (EVGN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 15, 2010. As of the latest trading session, EVGN stock price is $0.61, with a market capitalization of $5.1M. The stock has returned -47.16% over the past 12 months and -45.72% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Evogene Ltd. stock is Buy, with an average 12-month price target of $2.15. In fiscal year 2025, Evogene Ltd. reported revenue of $3.9M and net income of -$8.5M. For detailed data — including Evogene Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Evogene Ltd. (EVGN) stock price is $0.61. The stock is traded on NASDAQ under the ticker symbol EVGN. The 52-week range is $0.52 – $2.42.